SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO) announces that the company has entered into a distribution agreement with Phadia France. As of 1 January 2008, Aerocrine has granted Phadia the right to market and sell NIOX MINO® on the French market. Phadia, a world-leader within allergy diagnostics, already sells Aerocrine products in Spain. In France about 4 million people have diagnosed asthma and the prevalence of asthma like symptoms is even higher, about 15%.
